Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Item
http://www.wikidata.org/entity/Q37535964
Acute effects of cinacalcet on arterial stiffness and ventricular function in hemodialysis patients: A randomized double-blinded crossover study.Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy.Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsLC-MS/MS determination of cinacalcet enantiomers in rat plasma on Chirobiotic V column in polar ionic mode: application to a pharmacokinetic study.Comparison of AMG 416 and cinacalcet in rodent models of uremiaParathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort studyAn open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.Hypercalcemia in pregnancy - a multifaceted challenge: case reports and literature review.Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study.Clinical utilization of cinacalcet in hypercalcemic conditions.Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoCinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses.
P2860

Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Item
http://www.wikidata.org/entity/Q37535964
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
type
label
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
prefLabel
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.
@en
P2093
P2860
P2888
P304
P31
P356
10.2165/00003088-200948050-00002
P433
P478
P577
P6179
P698